The pieces....Joe's words.....
I'd like to take the time to remind everyone of all the accomplishments of
these past ten months--and it's a lot. We've acquired controlling interest in
Olaregen, plus more ownership throughout the last ten months; we've
acquired controlling interest in Regentys, we've acquired Pantheon, we've
acquired MediSource, we've acquired an MSO from Veneto, and still awaiting other assets that have not delivered to Generex as well as other
things outlined in the APA, but we're working on that.
We started our Merck Keytruda A37 and recruitment is ongoing for triplenegative breast cancer, and we're quite excited about this trial. We've
developed a new product, which we would announce soon; this product is
being packaged, and the launch materials are almost complete.
Close to 21 million shares of stock from two insiders--myself and Larry
Salvo, our board member--and two outsiders, were put back into treasury for
the benefit of the company and the shareholders just recently.
We've developed the DME-IQ and once our S-1 funding, we would launch
that program in its entirety.
We've completed our NGIO dividend and now we are in the final steps of
spinning it out.
There were many, many more executable s and accomplishments we've
completed this year and we just don't have the time to go through them all.
But I thought it was worth reminding everyone of the larger, valuable
initiatives we have completed in just a short amount of time--ten months.
This month also announced the final deal docs have been signed with
ALTuCELL.
The resources...
Our S-1 gives us the ability, once filed, to raise significant monies, a
crucial checkbox, which is our going concern. I'm happy to announce
Generex received, Wednesday--just this past Wednesday--the final
documents for our investments totaling $40 million. The lawyers would
review today, and if the last changes have been made, I will sign these
documents sometime next week as the board approval on the deals.
Then we will add to it, the S-1 filing as we are still looking into other equity
investment opportunities, we've been discussing with our investment bank
and other funds that have shown extreme interest. And now that the S-1 is
complete, this would meet those funding criteria for investment.
I'd like to take the time to remind everyone of all the accomplishments of
these past ten months--and it's a lot. We've acquired controlling interest in
Olaregen, plus more ownership throughout the last ten months; we've
acquired controlling interest in Regentys, we've acquired Pantheon, we've
acquired MediSource, we've acquired an MSO from Veneto, and still awaiting other assets that have not delivered to Generex as well as other
things outlined in the APA, but we're working on that.
We started our Merck Keytruda A37 and recruitment is ongoing for triplenegative breast cancer, and we're quite excited about this trial. We've
developed a new product, which we would announce soon; this product is
being packaged, and the launch materials are almost complete.
Close to 21 million shares of stock from two insiders--myself and Larry
Salvo, our board member--and two outsiders, were put back into treasury for
the benefit of the company and the shareholders just recently.
We've developed the DME-IQ and once our S-1 funding, we would launch
that program in its entirety.
We've completed our NGIO dividend and now we are in the final steps of
spinning it out.
There were many, many more executable s and accomplishments we've
completed this year and we just don't have the time to go through them all.
But I thought it was worth reminding everyone of the larger, valuable
initiatives we have completed in just a short amount of time--ten months.
This month also announced the final deal docs have been signed with
ALTuCELL.
The resources...
Our S-1 gives us the ability, once filed, to raise significant monies, a
crucial checkbox, which is our going concern. I'm happy to announce
Generex received, Wednesday--just this past Wednesday--the final
documents for our investments totaling $40 million. The lawyers would
review today, and if the last changes have been made, I will sign these
documents sometime next week as the board approval on the deals.
Then we will add to it, the S-1 filing as we are still looking into other equity
investment opportunities, we've been discussing with our investment bank
and other funds that have shown extreme interest. And now that the S-1 is
complete, this would meet those funding criteria for investment.
